{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:59:33Z","timestamp":1791197973219,"version":"4.1.0"},"reference-count":209,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bacillus Calmette\u2013Gu\u00e9rin (BCG) remains the frontline immunotherapy for non\u2013muscle-invasive bladder cancer (NMIBC), yet recurrence and non-response occur in over half of patients, highlighting the need for improved therapeutic strategies. Recent advances in bioengineering including genetic modification, synthetic biology, biomaterials, and delivery systems are expanding BCG from a traditional vaccine into a more versatile immunotherapeutic platform. In this review, we summarize the mechanisms of BCG-induced antitumor immunity and discuss current bioengineering strategies aimed at enhancing tumor interaction, innate immune activation, and modulation of the tumor immune microenvironment (TIME). We further highlight emerging approaches in delivery system design to improve intravesical retention and therapeutic efficacy. In addition, we discuss evolving perspectives on immune regulation in BCG therapy, including the potential contribution of type 2 immunity alongside canonical type 1 responses, as well as the role of trained immunity in sustaining antitumor effects. Finally, we outline key challenges for clinical translation and future directions toward more rational and precise BCG-based immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1888889","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:05:21Z","timestamp":1791194721000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioengineering strategies to enhance BCG immunotherapy against bladder cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Senhao","family":"Li","sequence":"first","affiliation":[{"name":"Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haige","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Feng","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Functional Nucleic Acids for Basic and Clinical Application, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.13.04109","article-title":"The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040","volume":"13","author":"Zhang","year":"2023","journal-title":"J Glob Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat Rev Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03376-9","article-title":"Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer","volume":"72","author":"Semeniuk-Wojtas","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00212-24","article-title":"BCG therapy in bladder cancer and its tumor microenvironment interactions","volume":"38","author":"Jian","year":"2025","journal-title":"Clin Microbiol Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133073","article-title":"BCG in bladder cancer immunotherapy","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S464068","article-title":"Bacillus calmette-guerin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC): current guidance and experience from clinical practice","volume":"16","author":"Naselli","year":"2024","journal-title":"Res Rep Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017913","article-title":"Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study","volume":"7","author":"Oughton","year":"2017","journal-title":"BMJ Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16081067","article-title":"Revitalizing bacillus calmette-guerin immunotherapy for bladder cancer: nanotechnology and bioengineering approaches","volume":"16","author":"Lv","year":"2024","journal-title":"Pharmaceutics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03729-5","article-title":"Comparative study on the efficacy of low-dose and full-dose BCG bladder perfusion therapy","volume":"27","author":"Lv","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31020079","article-title":"BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer","volume":"31","author":"Lidagoster","year":"2024","journal-title":"Curr Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.09.053","article-title":"Effects of Mycobacterium bovis Calmette et Guerin (BCG) in oncotherapy: Bladder cancer and beyond","volume":"39","author":"Mukherjee","year":"2021","journal-title":"Vaccine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.52547\/ibj.3676","article-title":"Role of intravesical BCG as a therapeutic vaccine for treatment of bladder carcinoma","volume":"26","author":"Doroud","year":"2022","journal-title":"Iran BioMed J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26413","article-title":"Fibronectin attachment protein from bacillus Calmette-Guerin as targeting agent for bladder tumor cells","volume":"131","author":"Coon","year":"2012","journal-title":"Int J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-5-8","article-title":"BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking","volume":"5","author":"Chen","year":"2005","journal-title":"BMC Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101832","article-title":"The role of caspase-8 in inflammatory signalling and pyroptotic cell death","volume":"70","author":"Pang","year":"2023","journal-title":"Semin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.20.6.823","article-title":"Cathepsin B is involved in the apoptosis intrinsic pathway induced by Bacillus Calmette-Guerin in transitional cancer cell lines","volume":"20","author":"Sandes","year":"2007","journal-title":"Int J Mol Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.05.115","article-title":"H2O2 generation by bacillus Calmette-Guerin induces the cellular oxidative stress response required for bacillus Calmette-Guerin direct effects on urothelial carcinoma biology","volume":"192","author":"Shah","year":"2014","journal-title":"J Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08274.x","article-title":"Bacille-Calmette Guerin induces caspase-independent cell death in urothelial carcinoma cells together with release of the necrosis-associated chemokine high molecular group box protein 1","volume":"103","author":"See","year":"2009","journal-title":"BJU Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2908295","article-title":"Update on the mechanism of action of intravesical BCG therapy to treat non-muscle-invasive bladder cancer","volume":"29","author":"Abou Chakra","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1242\/bio.032045","article-title":"Enhanced survival of BCG-stimulated dendritic cells: involvement of anti-apoptotic proteins and NF-kappaB","volume":"7","author":"Kumar","year":"2018","journal-title":"Biol Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004325","article-title":"Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors","volume":"10","author":"Moreo","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2026.114676","article-title":"BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4(+) Th1 responses","volume":"29","author":"Rollin","year":"2026","journal-title":"iScience"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200442","article-title":"Divergent macrophage-regulated T cell states determine response to Bacillus Calmette-Guerin vaccine in high-risk bladder cancer","volume":"136","author":"Brown","year":"2026","journal-title":"J Clin Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162148","article-title":"A model to explain how the bacille calmette guerin (BCG) vaccine drives interleukin-12 production in neonates","volume":"11","author":"Kativhu","year":"2016","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13046-024-03121-9","article-title":"Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling","volume":"43","author":"Monti","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed8030140","article-title":"Discrepancy in Response of Mouse Dendritic Cells against BCG: Weak Immune Effects of Plasmacytoid Dendritic Cells Compared to Classical Dendritic Cells despite the Uptake of Bacilli","volume":"8","author":"Meng","year":"2023","journal-title":"Trop Med Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31911","article-title":"Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase","volume":"117","author":"Sharma","year":"2007","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-0346-4","article-title":"Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer","volume":"17","author":"van Puffelen","year":"2020","journal-title":"Nat Rev Urol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12967-025-06358-w","article-title":"Spatial relationships and interactions of immune cell niches are linked to the pathologic response of muscle-invasive bladder cancer to neoadjuvant therapy","volume":"23","author":"Wahafu","year":"2025","journal-title":"J Transl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-60910-2","article-title":"Memory B cells in mature follicle-like tertiary lymphoid structures predict BCG response in non-muscle-invasive bladder cancer","author":"Wang","year":"2026","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12935-025-03676-3","article-title":"Mcl-1 downregulation enhances BCG treatment efficacy in bladder cancer by promoting macrophage polarization","volume":"25","author":"Tan","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20010601)92:5<697::aid-ijc1245>3.0.co;2-z","article-title":"NK cells are essential for effective BCG immunotherapy","volume":"92","author":"Brandau","year":"2001","journal-title":"Int J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00284","article-title":"NKG2D is a key receptor for recognition of bladder cancer cells by IL-2-activated NK cells and BCG promotes NK cell activation","volume":"6","author":"Garcia-Cuesta","year":"2015","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1614857","article-title":"Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial","volume":"8","author":"Ji","year":"2019","journal-title":"Oncoimmunology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41577-025-01209-7","article-title":"BCG plus beta-glucan trains neutrophils to beat bladder cancer","volume":"25","author":"Bird","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.735590","article-title":"Optimization of BCG therapy targeting neutrophil extracellular traps, autophagy, and miRNAs in bladder cancer: implications for personalized medicine","volume":"8","author":"Mao","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801022","article-title":"Identification of neoantigen-reactive tumor-infiltrating lymphocytes in primary bladder cancer","volume":"202","author":"Leko","year":"2019","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0285","article-title":"gammadelta T Cells Support Antigen-Specific alphabeta T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer","volume":"9","author":"Ji","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040773","article-title":"IL-17 production by gammadelta T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guerin treatment against bladder cancer","volume":"41","author":"Takeuchi","year":"2011","journal-title":"Eur J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2160094","article-title":"BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and gammadelta T-cells that can be further expanded in vitro","volume":"12","author":"Esteso","year":"2023","journal-title":"Oncoimmunology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111892","article-title":"The quantity, function and anti-tumor effect of Mucosal associated invariant T cells in patients with bladder cancer","volume":"133","author":"Zhang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12967-023-03944-8","article-title":"BCG-induced trained immunity: history, mechanisms and potential applications","volume":"21","author":"Chen","year":"2023","journal-title":"J Transl Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005518","article-title":"Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections","volume":"11","author":"Graham","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.7066","article-title":"Innate immune memory is associated with increased disease-free survival in bladder cancer patients treated with bacillus Calmette-Guerin","volume":"15","author":"Graham","year":"2021","journal-title":"Can Urol Assoc J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.05.002","article-title":"Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity","volume":"43","author":"Daman","year":"2025","journal-title":"Cancer Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.05.026","article-title":"A fungal-derived adjuvant amplifies the antitumoral potency of Bacillus Calmette-Guerin via reprogramming granulopoiesis","volume":"58","author":"Jurado","year":"2025","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk8093","article-title":"Multi-omics analysis reveals that linoleic acid metabolism is associated with variations of trained immunity induced by distinct BCG strains","volume":"10","author":"Xu","year":"2024","journal-title":"Sci Adv"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004485","article-title":"Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer","volume":"10","author":"Buffen","year":"2014","journal-title":"PloS Pathog"},{"key":"B52","doi-asserted-by":"publisher","first-page":"181987","DOI":"10.1155\/2012\/181987","article-title":"Bladder cancer immunotherapy: BCG and beyond","volume":"2012","author":"Askeland","year":"2012","journal-title":"Adv Urol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/iep.12392","article-title":"Correlation between aryl hydrocarbon receptor and IL-17(+) and Foxp3(+) T-cell infiltration in bladder cancer","volume":"102","author":"Fattahi","year":"2021","journal-title":"Int J Exp Pathol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2013.06.032","article-title":"Involvement of Th17 cells in patients of urothelial carcinoma of bladder","volume":"74","author":"Chugh","year":"2013","journal-title":"Hum Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090207","article-title":"IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway","volume":"206","author":"Wang","year":"2009","journal-title":"J Exp Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12935-024-03525-9","article-title":"Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies","volume":"24","author":"Anvar","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190456","article-title":"Targeting the interleukin-17 immune axis for cancer immunotherapy","volume":"217","author":"Vitiello","year":"2020","journal-title":"J Exp Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15711","article-title":"Rationalizing heptadecaphobia: T(H) 17 cells and associated cytokines in cancer and metastasis","volume":"288","author":"Lucke","year":"2021","journal-title":"FEBS J"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0267","article-title":"Intravesical BCG induces CD4(+) T-cell expansion in an immune competent model of bladder cancer","volume":"5","author":"Kates","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240045","article-title":"Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment","volume":"221","author":"Tran","year":"2024","journal-title":"J Exp Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.05.017","article-title":"Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer","volume":"181","author":"Oh","year":"2020","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1945-z","article-title":"Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer","volume":"66","author":"Pichler","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112471","article-title":"The glycolysis\/HIF-1alpha axis defines the inflammatory role of IL-4-primed macrophages","volume":"42","author":"Dang","year":"2023","journal-title":"Cell Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.7150\/jca.90085","article-title":"BCG immunotherapy promotes tumor-derived T-cell activation through the FLT3\/FLT3LG pathway in bladder cancer","volume":"15","author":"Zhang","year":"2024","journal-title":"J Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615091","article-title":"Immunological hallmarks for clinical response to BCG in bladder cancer","volume":"11","author":"Lim","year":"2020","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34897","article-title":"Systemic versus localized Bacillus Calmette Guerin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity","volume":"155","author":"Atallah","year":"2024","journal-title":"Int J Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094776","article-title":"Spatial distribution of macrophage and lymphocyte subtypes within tumor microenvironment to predict recurrence of non-muscle-invasive papillary urothelial carcinoma after BCG immunotherapy","volume":"25","author":"Drachneris","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1416","article-title":"Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses","volume":"66","author":"Suttmann","year":"2006","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-8-6","article-title":"Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)","volume":"8","author":"Saban","year":"2007","journal-title":"BMC Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/BF00941903","article-title":"Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer","volume":"25","author":"de Boer","year":"1997","journal-title":"Urol Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02883-5","article-title":"Temporal dynamics of immune cell patterns in bladder cancer patients receiving Bacillus Calmette-Guerin therapy","volume":"131","author":"Lu","year":"2024","journal-title":"Br J Cancer"},{"key":"B72","article-title":"BCG prophylaxis in bladder cancer produces activation of recruited neutrophils","volume":"18","author":"Vita","year":"2011","journal-title":"Can J Urol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.11.045","article-title":"The role of granulocytes following intravesical BCG prophylaxis","volume":"51","author":"Siracusano","year":"2007","journal-title":"Eur Urol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-32-87","article-title":"Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer","volume":"32","author":"Suriano","year":"2013","journal-title":"J Exp Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)42445-1","article-title":"Role of fibronectin in intravesical BCG therapy for superficial bladder cancer","volume":"139","author":"Ratliff","year":"1988","journal-title":"J Urol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602026","article-title":"Role of urothelial cells in BCG immunotherapy for superficial bladder cancer","volume":"91","author":"Bevers","year":"2004","journal-title":"Br J Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)36052-4","article-title":"Fibronectin expression on surgical specimens correlated with the response to intravesical bacillus Calmette-Guerin therapy","volume":"149","author":"Fleischmann","year":"1993","journal-title":"J Urol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41467-020-15030-4","article-title":"Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat Commun"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344300","article-title":"Restoration of innate immune activation accelerates Th1-cell priming and protection following pulmonary mycobacterial infection","volume":"44","author":"Lai","year":"2014","journal-title":"Eur J Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003939","article-title":"FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer","volume":"10","author":"Zhang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.08.010","article-title":"Discovery of antimicrobial peptides in urinary tract infections","volume":"10","author":"Voss","year":"2024","journal-title":"Eur Urol Focus"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00336-06","article-title":"A functional dlt operon, encoding proteins required for incorporation of d-alanine in teichoic acids in gram-positive bacteria, confers resistance to cationic antimicrobial peptides in Streptococcus pneumoniae","volume":"188","author":"Kovacs","year":"2006","journal-title":"J Bacteriol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.045997-0","article-title":"The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile","volume":"157","author":"McBride","year":"2011","journal-title":"Microbiol (Reading)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"964\u2013","DOI":"10.1016\/j.urology.2014.12.028","article-title":"Modulating the internalization of bacille Calmette-Guerin by cathelicidin in bladder cancer cells","volume":"85","author":"Choi","year":"2015","journal-title":"Urology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20200602","article-title":"Emerging treatments for bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer","volume":"62","author":"Kim","year":"2021","journal-title":"Investig Clin Urol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20210425","article-title":"Immunotherapeutic effects of recombinant Bacillus Calmette-Guerin containing sic gene in ex vivo and in vivo bladder cancer models","volume":"63","author":"Kim","year":"2022","journal-title":"Investig Clin Urol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.12.097","article-title":"The immunotherapeutic effects of recombinant Bacillus Calmette-Guerin resistant to antimicrobial peptides on bladder cancer cells","volume":"509","author":"Cho","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00217-24","article-title":"The SapM phosphatase can arrest phagosome maturation in an ESX-1 independent manner in Mycobacterium tuberculosis and BCG","volume":"92","author":"Xander","year":"2024","journal-title":"Infect Immun"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01131-25","article-title":"Assembly of the Mycobacterium tuberculosis type VII ESX-1 secretion system in Mycobacterium smegmatis identifies a new transcriptional activator of esx-1 genes and a novel TB vaccine","volume":"13","author":"Zriba","year":"2025","journal-title":"Microbiol Spectr"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01147","article-title":"The recombinant Bacille Calmette-Guerin vaccine VPM1002: Ready for clinical efficacy testing","volume":"8","author":"Nieuwenhuizen","year":"2017","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.9.5299","article-title":"Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes","volume":"95","author":"Hess","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065509","article-title":"Safety and immunogenicity of recombinant Bacille Calmette-Guerin strain VPM1002 and its derivatives in a goat model","volume":"24","author":"Figl","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.12.006","article-title":"A phase 1\/2 single-arm clinical trial of recombinant Bacillus Calmette-Guerin (BCG) VPM1002BC immunotherapy in non-muscle-invasive bladder cancer recurrence after conventional BCG therapy: SAKK 06\/14","volume":"5","author":"Rentsch","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2017.00154","article-title":"A novel role of Listeria monocytogenes membrane vesicles in inhibition of autophagy and cell death","volume":"7","author":"Vdovikova","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/toxins9090273","article-title":"Listeriolysin O regulates the expression of Optineurin, an autophagy adaptor that inhibits the growth of Listeria monocytogenes","volume":"9","author":"Puri","year":"2017","journal-title":"Toxins (Basel)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2021.1969765","article-title":"Macrophages target Listeria monocytogenes by two discrete non-canonical autophagy pathways","volume":"18","author":"Gluschko","year":"2022","journal-title":"Autophagy"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjac015","article-title":"The molecular regulation of autophagy in antimicrobial immunity","volume":"14","author":"Qin","year":"2022","journal-title":"J Mol Cell Biol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/toxics12070491","article-title":"Widespread myalgia and chronic fatigue: Phagocytes from macrophagic myofasciitis patients exposed to aluminum oxyhydroxide-adjuvanted vaccine exhibit specific inflammatory, autophagic, and mitochondrial responses","volume":"12","author":"Masson","year":"2024","journal-title":"Toxics"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46040220","article-title":"Inflammasome molecular insights in autoimmune diseases","volume":"46","author":"Neamtu","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102681","article-title":"Autoimmunity, epitope analysis, and molecular mimicry","volume":"97","author":"Rojas","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.13175","article-title":"Why is Listeria monocytogenes such a potent inducer of CD8+ T-cells","volume":"22","author":"Chavez-Arroyo","year":"2020","journal-title":"Cell Microbiol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19531","article-title":"Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy","volume":"8","author":"Medrano","year":"2017","journal-title":"Oncotarget"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1002\/med.21649","article-title":"Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy","volume":"40","author":"Wu","year":"2020","journal-title":"Med Res Rev"},{"key":"B104","doi-asserted-by":"publisher","first-page":"9934","DOI":"10.1038\/s41467-024-54293-z","article-title":"Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy","volume":"15","author":"Choi","year":"2024","journal-title":"Nat Commun"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-1022","article-title":"STING agonist VB-85247 induces durable antitumor immune responses by intravesical administration in a non-muscle-invasive bladder cancer","volume":"85","author":"Prabagar","year":"2025","journal-title":"Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fruro.2023.984967","article-title":"Mutations in genes encoding innate immune molecules identified in bladder cancer samples as potential biomarkers for immunotherapy with BCG and agonists","volume":"3","author":"de Queiroz","year":"2023","journal-title":"Front Urol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/path.5830","article-title":"BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer","volume":"256","author":"Lombardo","year":"2022","journal-title":"J Pathol"},{"key":"B108","doi-asserted-by":"crossref","DOI":"10.1101\/2023.12.15.571740","article-title":"Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist","volume-title":"Biorxiv","author":"Um","year":"2023"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115487","article-title":"Itaconic acid and dimethyl itaconate exert antibacterial activity in carbon-enriched environments through the TCA cycle","volume":"167","author":"Xie","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2009-0040OC","article-title":"Enhancement of Th1 lung immunity induced by recombinant Mycobacterium bovis Bacillus Calmette-Guerin attenuates airway allergic disease","volume":"43","author":"Christ","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.943558","article-title":"Recombinant BCG expressing the LTAK63 adjuvant improves a short-term chemotherapy schedule in the control of tuberculosis in mice","volume":"13","author":"Trentini","year":"2022","journal-title":"Front Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01460","article-title":"In vitro evidence of human immune responsiveness shows the improved potential of a recombinant BCG strain for bladder cancer treatment","volume":"10","author":"Rodriguez","year":"2019","journal-title":"Front Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9630793","article-title":"A bivalent recombinant Mycobacterium bovis BCG expressing the S1 subunit of the pertussis toxin induces a polyfunctional CD4(+) T cell immune response","volume":"2019","author":"Kanno","year":"2019","journal-title":"BioMed Res Int"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.118329","article-title":"rBCG-LTAK63 outperforms BCG in bladder cancer immunotherapy: Dendritic and T cell coordination drives superior tumor control in a mouse model","volume":"22","author":"de Almeida","year":"2026","journal-title":"Int J Biol Sci"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.79","article-title":"Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guerin","volume":"10","author":"Liu","year":"2014","journal-title":"Future Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1070383","article-title":"Tumor microenvironment and epithelial-mesenchymal transition in bladder cancer: Cytokines in the game?","volume":"9","author":"Martins-Lima","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B117","article-title":"Bladder cancer immunological background and biomarkers","volume":"73","author":"Vales-Gomez","year":"2020","journal-title":"Arch Esp Urol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002304","article-title":"Key immune cells and their crosstalk in the tumor microenvironment of bladder cancer: Insights for innovative therapies","volume":"6","author":"Di Spirito","year":"2025","journal-title":"Explor Target Antitumor Ther"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(05)67417-4","article-title":"Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2","volume":"164","author":"Yamada","year":"2000","journal-title":"J Urol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02522.x","article-title":"Recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity","volume":"137","author":"Luo","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2016.03.007","article-title":"Antitumor activity of recombinant Bacille Calmette-Guerin secreting interleukin-15-Ag85B fusion protein against bladder cancer","volume":"35","author":"Takeuchi","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200403000-00005","article-title":"Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma","volume":"27","author":"Arnold","year":"2004","journal-title":"J Immunother"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0673-z","article-title":"Recombinant bacillus Calmette-Guerin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro","volume":"58","author":"Liu","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0137","article-title":"Gmcsf and Ifnalpha gene therapy improves the response to BCG immunotherapy in a murine model of bladder cancer","volume":"16","author":"Tham","year":"2020","journal-title":"Future Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3390\/cells13231937","article-title":"Exploring the immunoresponse in bladder cancer immunotherapy","volume":"13","author":"Ruiz-Lorente","year":"2024","journal-title":"Cells"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030357","article-title":"New perspectives in the medical treatment of non-muscle-invasive bladder cancer: Immune checkpoint inhibitors and beyond","volume":"11","author":"Audisio","year":"2022","journal-title":"Cells"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S165840","article-title":"Bacillus Calmette-Guerin and anti-PD-L1 combination therapy boosts immune response against bladder cancer","volume":"11","author":"Wang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with Bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"102059","DOI":"10.1016\/j.clgc.2024.02.010","article-title":"Urinary bother, urinalysis, and two-year efficacy follow-up results of phase I trial of intravesical Bacillus Calmette-Guerin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guerin treatment","volume":"22","author":"Montgomery","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: The randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.10.041","article-title":"Persistent BCG bacilli perpetuate CD4 T effector memory and optimal protection against tuberculosis","volume":"32","author":"Kaveh","year":"2014","journal-title":"Vaccine"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.11.005","article-title":"Evidence for enhanced central memory priming by live Mycobacterium bovis BCG vaccine in comparison with killed BCG formulations","volume":"26","author":"Whelan","year":"2008","journal-title":"Vaccine"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/s1567-5769(01)00055-8","article-title":"Development of immunoadjuvants for immunotherapy of cancer","volume":"1","author":"Azuma","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.15430\/JCP.25.002","article-title":"Bladder cancer medication Bacillus Calmette-Guerin-cell wall skeleton focusing on alternatives and developments to limitations","volume":"30","author":"Lee","year":"2025","journal-title":"J Cancer Prev"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1007\/BF00205355","article-title":"Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial","volume":"14","author":"Ochiai","year":"1983","journal-title":"Cancer Immunol Immunother"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.5c06464","article-title":"Transition temperature-guided design of lipid nanoparticles for effective mRNA delivery","volume":"17","author":"Shin","year":"2025","journal-title":"ACS Appl Mater Interfaces"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.2174\/0113894501384020250804093144","article-title":"Development of novel intravesical formulation for bladder retention targeting bladder disorders","author":"Harle","year":"2025","journal-title":"Curr Drug Targets"},{"key":"B138","article-title":"The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma","volume":"31","author":"Miyazaki","year":"2011","journal-title":"Anticancer Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903348","article-title":"Mycobacterium bovis bacillus Calmette-Guerin vaccination mobilizes innate myeloid-derived suppressor cells restraining in vivo T cell priming via IL-1R-dependent nitric oxide production","volume":"184","author":"Martino","year":"2010","journal-title":"J Immunol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"14933","DOI":"10.1038\/s41598-021-94529-2","article-title":"BCG therapy is associated with long-term, durable induction of Treg signature genes by epigenetic modulation","volume":"11","author":"Keefe","year":"2021","journal-title":"Sci Rep"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2007.03.017","article-title":"New packaging method of mycobacterial cell wall using octaarginine-modified liposomes: Enhanced uptake by and immunostimulatory activity of dendritic cells","volume":"120","author":"Homhuan","year":"2007","journal-title":"J Control Release"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.PSIB-0001-2018","article-title":"Liposome-encapsulated Bacillus Calmette-Guerin cell wall skeleton enhances antitumor efficiency for bladder cancer in vitro and in vivo via induction of AMP-activated protein kinase","volume":"12","author":"Whang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.10056.x","article-title":"The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guein can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands","volume":"108","author":"Miyazaki","year":"2011","journal-title":"BJU Int"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/4312908","article-title":"Advances in bacterial lysate immunotherapy for infectious diseases and cancer","volume":"2024","author":"Rahman","year":"2024","journal-title":"J Immunol Res"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.151215","article-title":"Thermosensitive hydrogel delivery of BCG lysates and tumor antigens: A novel strategy for melanoma immunoprevention and therapeutics","volume":"745","author":"Chen","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004133","article-title":"BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma","volume":"10","author":"Kremenovic","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101433","article-title":"Outer membrane vesicle vaccines","volume":"50","author":"Micoli","year":"2020","journal-title":"Semin Immunol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.PSIB-0001-2018","article-title":"Outer membrane vesicle-host cell interactions","volume":"7","author":"Cecil","year":"2019","journal-title":"Microbiol Spectr"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-025-00984-8","article-title":"Bacterial nanoparticles as a potent and safe alternative to BCG for bladder cancer immunotherapy","volume":"33","author":"Colson","year":"2025","journal-title":"Cancer Gene Ther"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00794-4","article-title":"Mycobacterium bovis bacille Calmette-Guerin-derived extracellular vesicles as an alternative to live BCG immunotherapy","volume":"23","author":"Gellings","year":"2023","journal-title":"Clin Exp Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010211","article-title":"The progress of chitosan-based nanoparticles for intravesical bladder cancer treatment","volume":"15","author":"Yu","year":"2023","journal-title":"Pharmaceutics"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17070868","article-title":"Chitosan nanoparticles enhance the antiproliferative effect of lapachol in urothelial carcinoma cell lines","volume":"17","author":"Amparo","year":"2025","journal-title":"Pharmaceutics"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2009.09.004","article-title":"Biodegradation, biodistribution and toxicity of chitosan","volume":"62","author":"Kean","year":"2010","journal-title":"Adv Drug Delivery Rev"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2001.tb01116.x","article-title":"Chitosan induces apoptosis via caspase-3 activation in bladder tumor cells","volume":"92","author":"Hasegawa","year":"2001","journal-title":"Jpn J Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1166\/jnn.2015.11690","article-title":"Antitumor efficacy of Bacillus Calmette-Guerin loaded cationic nanoparticles for intravesical immunotherapy of bladder tumor induced rat model","volume":"15","author":"Erdo\u011far","year":"2015","journal-title":"J Nanosci Nanotechnol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.04.033","article-title":"Development of a thermoresponsive chitosan gel combined with human mesenchymal stem cells and desferrioxamine as a multimodal pro-angiogenic therapeutic for the treatment of critical limb ischaemia","volume":"161","author":"Hastings","year":"2012","journal-title":"J Control Release"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1080\/09205063.2013.789357","article-title":"A novel chitosan-based thermosensitive hydrogel containing doxorubicin liposomes for topical cancer therapy","volume":"24","author":"Wang","year":"2013","journal-title":"J Biomater Sci Polym Ed"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.2174\/0929867311302010009","article-title":"Thermosensitive polymeric hydrogels as drug delivery systems","volume":"20","author":"Gong","year":"2013","journal-title":"Curr Med Chem"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2012.10.077","article-title":"Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer","volume":"34","author":"Bae","year":"2013","journal-title":"Biomaterials"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2011.11.068","article-title":"Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization","volume":"33","author":"Wu","year":"2012","journal-title":"Biomaterials"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2013.09.027","article-title":"A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette-Guerin in the treatment of bladder cancer","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2009.01.018","article-title":"Chitosan-dibasic orthophosphate hydrogel: a potential drug delivery system","volume":"371","author":"Ta","year":"2009","journal-title":"Int J Pharm"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59071286","article-title":"Evaluation of possible side effects in the treatment of urinary incontinence with magnetic stimulation","volume":"59","author":"Pavcnik","year":"2023","journal-title":"Med (Kaunas)"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030300","article-title":"Magnetic hyperthermia therapy for high-grade glioma: a state-of-the-art review","volume":"17","author":"Rodriguez","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03729-3","article-title":"Magnetic hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent\/progressive glioblastoma: a systematic review","volume":"152","author":"Shirvalilou","year":"2021","journal-title":"J Neuro-Oncol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041145","article-title":"High efficacy on the death of breast cancer cells using SPMHT with magnetite cyclodextrins nanobioconjugates","volume":"15","author":"Caizer","year":"2023","journal-title":"Pharmaceutics"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010033","article-title":"Local magnetic hyperthermia and systemic gemcitabine\/paclitaxel chemotherapy triggers neo-angiogenesis in orthotopic pancreatic tumors without involvement of auto\/paracrine tumor cell VEGF signaling and hypoxia","volume":"16","author":"Maduabuchi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2021.1919441","article-title":"Hyperthermia generated by magnetic nanoparticles for effective treatment of disseminated peritoneal cancer in an orthotopic nude-mouse model","volume":"20","author":"Matsumi","year":"2021","journal-title":"Cell Cycle"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0597-9","article-title":"Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers","volume":"51","author":"Leakakos","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202310735","article-title":"Drug-loaded Bacillus Calmette-Guerin bacteria for immuno-chemo combo therapy in bladder cancer","volume":"36","author":"Liu","year":"2024","journal-title":"Adv Mater"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.11855","article-title":"OSU-T315 and doxorubicin synergistically induce apoptosis via mitochondrial pathway in bladder cancer cells","volume":"46","author":"Li","year":"2022","journal-title":"Cell Biol Int"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2021.1991316","article-title":"Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy","volume":"21","author":"Sohail","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202205630","article-title":"Long-term retention microbubbles with three-layer structure for floating intravesical instillation delivery","volume":"19","author":"Deng","year":"2023","journal-title":"Small"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.8b00421","article-title":"Ultrasound technology for molecular imaging: from contrast agents to multimodal imaging","volume":"4","author":"Li","year":"2018","journal-title":"ACS Biomater Sci Eng"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.8b03674","article-title":"Ultrasound triggered conversion of porphyrin\/camptothecin-fluoroxyuridine triad microbubbles into nanoparticles overcomes multidrug resistance in colorectal cancer","volume":"12","author":"Chen","year":"2018","journal-title":"ACS Nano"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c06540","article-title":"Prolonged release of Bacillus Calmette-Guerin by floating microbubbles to enhance intravesical immunotherapy for bladder cancer","volume":"19","author":"Tang","year":"2025","journal-title":"ACS Nano"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1039\/d4sc07198k","article-title":"Engineering live cell surfaces with polyphenol-functionalized nanoarchitectures","volume":"16","author":"He","year":"2025","journal-title":"Chem Sci"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.5c00271","article-title":"Regulating bacteria-host interactions for disease intervention by covalent conjugation of bacterial surface","volume":"58","author":"Chen","year":"2025","journal-title":"Acc Chem Res"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2026.174139","article-title":"Armouring Bacillus Calmette-Gu\u00e9rin with metal-phenolic networks for bladder cancer therapy","volume":"531","author":"Zhang","year":"2026","journal-title":"Chem Eng J"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.10.005","article-title":"An immunostimulatory liponanogel reveals immune activation-enhanced drug delivery and therapeutic efficacy in cancer","volume":"376","author":"Li","year":"2024","journal-title":"J Control Release"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202314501","article-title":"Metal-phenolic nanocloaks on cancer cells potentiate STING pathway activation for synergistic cancer immunotherapy","volume":"63","author":"He","year":"2024","journal-title":"Angew Chem Int Ed Engl"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.01.036","article-title":"Maintaining manganese in tumor to activate cGAS-STING pathway evokes a robust abscopal anti-tumor effect","volume":"331","author":"Wang","year":"2021","journal-title":"J Control Release"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081783","article-title":"Bacteria for treatment: Microbiome in bladder cancer","volume":"10","author":"Min","year":"2022","journal-title":"Biomedicines"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000003303.08","article-title":"Pd25-08\u2003the bladder tumor microbiome may augment response to Bcg in non-muscle invasive bladder cancer","volume":"209","author":"Lone","year":"2023","journal-title":"J Urol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-026-01002-x","article-title":"Intravesical mycobacteria reshape bladder and gut microbiota in a murine bladder cancer model","volume":"12","author":"Campo-Perez","year":"2026","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1479795","article-title":"Urinary microbiota changes among NMIBC patients during BCG therapy: comparing BCG responders and non-responders","volume":"15","author":"Boban","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-200277","article-title":"The urinary microbiome and bladder cancer: susceptibility and immune responsiveness","volume":"6","author":"Andolfi","year":"2020","journal-title":"Bladder Cancer"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S452377","article-title":"Experimental and new approaches for bladder preservation in intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC)","volume":"16","author":"Avilez","year":"2024","journal-title":"Res Rep Urol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010131","article-title":"Immune checkpoint inhibitors for the treatment of bladder cancer","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2024.105703","article-title":"BCG's role in strengthening immune responses: implications for tuberculosis and comorbid diseases","volume":"127","author":"Naqvi","year":"2025","journal-title":"Infect Genet Evol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00194-23","article-title":"Review of BCG immunotherapy for bladder cancer","volume":"38","author":"Liatsos","year":"2025","journal-title":"Clin Microbiol Rev"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.8.4246","article-title":"Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin","volume":"163","author":"O'Donnell","year":"1999","journal-title":"J Immunol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01734.x","article-title":"IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer","volume":"127","author":"Riemensberger","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04105.x","article-title":"Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guerin (BCG)-induced macrophage cytotoxicity against bladder cancer cells","volume":"160","author":"Luo","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004421117","article-title":"Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-gamma signaling","volume":"117","author":"Antonelli","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07962-4","article-title":"The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8(+) T cells against cancer","volume":"634","author":"Feng","year":"2024","journal-title":"Nature"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-3766.2012.05.003","article-title":"[Intravesical anchoring of streptavidin-tagged interleukin-4 fusion protein for immunotherapy of mouse superficial bladder cancer]","volume":"34","author":"Zhang","year":"2012","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59081452","article-title":"Diagnostic and prognostic roles of GATA3 immunohistochemistry in urothelial carcinoma","volume":"59","author":"Yoo","year":"2023","journal-title":"Med (Kaunas)"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.860663","article-title":"GATA3 predicts the tumor microenvironment phenotypes and molecular subtypes for bladder carcinoma","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Surg"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00660-9","article-title":"Beyond genetics: driving cancer with the tumour microenvironment behind the wheel","volume":"24","author":"Yuan","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1038\/s44222-022-00016-2","article-title":"Targeted modulation of immune cells and tissues using engineered biomaterials","volume":"1","author":"Yousefpour","year":"2023","journal-title":"Nat Rev Bioeng"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12661","article-title":"Genomic characterization of high-risk non-muscle invasive bladder cancer","volume":"7","author":"Meeks","year":"2016","journal-title":"Oncotarget"},{"key":"B203","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13073-020-00743-4","article-title":"MHC-I genotype and tumor mutational burden predict response to immunotherapy","volume":"12","author":"Goodman","year":"2020","journal-title":"Genome Med"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071356","article-title":"PD-L1 expression in high-risk non-muscle-invasive bladder cancer is influenced by intravesical Bacillus Calmette-Guerin (BCG) therapy","volume":"16","author":"Maas","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B205","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12894-024-01482-z","article-title":"PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors","volume":"24","author":"Plage","year":"2024","journal-title":"BMC Urol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00687-x","article-title":"Does immune cell exhaustion lie at the heart of BCG-unresponsive disease","volume":"20","author":"Ingersoll","year":"2023","journal-title":"Nat Rev Urol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109535","article-title":"Urine PD-L1 is a tumor tissue candidate substitute and is associated with poor survival in muscle-invasive bladder cancer patients","volume":"114","author":"Ma","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252011157","article-title":"Differential urinary microbiome and its metabolic footprint in bladder cancer patients following BCG treatment","volume":"25","author":"Min","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B209","volume-title":"Statpearls","author":"Johnson-Arbor","year":"2025"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1888889\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:05:24Z","timestamp":1791194724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1888889\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":209,"alternative-id":["10.3389\/fimmu.2026.1888889"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1888889","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1888889"}}